THE PROBLEM OF CHOICE OF H1-ANTAGONIST IN CLINICAL PRACTICE
Abstract
The overview of pharmacological properties of H1-antagonists was made on this paper. The conclusion was done, that for most clinical applications in outpatient conditions the drugs from II generation (“non-sedative generation”) are drugs of choice because they haven’t got any sedative properties. Fenkarol® (Quifenadine) has unique properties to accelerate destroying of histamine and to deplete it depot in tissues. Due to these properties Fenkarol® is one of the drug of choice from H1-antagonists for acute respiratory diseases treatment (common cold) and in complex medication for the treatment of bronchial asthma. As well Fenkarol® is one of the drug of choice for pediatric practice owing to the safety and long clinical experience of its use.
Keywords:
histamine, Н1 – blockers, allergy, in(ammation, spasmodic asthma. Quifenadine, (Fenkarol®).References
1. Геппе, Н.А. Cовременные антигистаминные и акарицидные препараты в борьбе с аллергическими заболеваниями/ Н. А. Геппе [и др.]//Terra medica. - №1. – 2005.
2. Кукес В. Г. Клиническая фармакология. Москва: ГЭОТАР МЕДИцИНА, 2004.
3. Машковский М. Д. Лекарственные средства. В 2-х томах, Москва: Медицина 1987, т. 1, C. 307-317.
4. Справочник Видаль. Лекарственные препараты в России, АОЗТ «АстраФармСервис», 2011.
5. Brunton, L. Laurence. Goodman & Gilman’s The Pharmacological Basis of Therapeutics / L. Laurence Brunton, John S. Lazo,Keith L. Parker. 11th Ed, N. Y., McGraw-Hill, 2006.
6. Carruthers, S. G. Melmon and Morrelli’s Clinical Pharmacology/ S. G. Carruthers [et al]. 4th Ed., McGraw –Hill, 2000.
7. Craig , Ch. Modern Pharmacology/ Charles R. Craig, Robert E. Stitzel. 6th Ed., Lippincott Williams & Wilkins, 2004.
8. Cooper, D. The Washington Manual of Medical Therapeutics/ D. Cooper [et al]. 32nd Ed, Lippincott Williams & Wilkins, 2007.
9. Dicpinigaitis, P. Effect of the second-generation antihistamine, fexofenadine, on cough reflex sensitivity and pulmonary function/ P.V. Dicpinigaitis, Y.E.Gayle. Br. J. Clin. Pharmacol. - 2003. – Vol. 56. – P. 501–504.
10. Katzung B. G. Basic & Clinical Pharmacology, 11th Ed., McGraw-Hill, 2009.
11. Kamienski M. Pharmacology demystified/M. Kamienski, J. E. Keogh. McGraw-Hill Professional, 2005 - P. 257.
12. Pharmindex Brevier/ Podręczny index leków. CMP Medica Poland, 2006.- L249.
13. Ritter, J. M. A Textbook of Clinical Pharmacology and Therapeutics/ J. M. Ritter [et al]. 5th Ed, Hodder Arnold, 2008.
Tarascon Pocket Pharmacopoeia. Loma Linda, CA: TP, 2010.
15. Yamauchi, K. Roles of histamine in the pathogenesis of bronchial asthma and reevaluation of the clinical usefulness of antihistamines/ K. Yamauchi [et al] //Yakugaku Zasshi. – 2011. –Vol. 131(2) – P. 185-191.
16. Weller, K. H1-Antihistamine up-dosing in chronic spontaneous urticaria: patients’ perspective of effectiveness and side effects – a retrospective survey study/ K. Weller [et al].–2011.- PLoS ONE 6(9): e23931. doi:10.1371/journal. pone. 0023931.
17. Wiest, E. Use of nonsedating antihistamines in the common cold/ E. Wiest, J. Jones// Emerg. Med. J. - 2011. – Vol. 28. – P. 632-633.
